This upregulation is mainly a consequence to the overexpression of the cyclin D1 protein, and not to gene amplification, which probably suggests the inclusion of the immunohistochemical expression of cyclin D1 in the global evaluation of melanomas, and opens the possibility of its use as a therapeutic target. The gene discussed is CCND1; the disease is melanoma.